Financials in USD. Standardized financial statements.
A compact view of how iSpecimen Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.93M | $9.29M | $9.93M | $10.40M | $11.14M | $8.18M | $4.30M | $4.39M |
| Revenue Growth? | -79.2% | -6.4% | -4.6% | -6.6% | +36.1% | +90.4% | -2.2% | 0.0% |
| Cost of Revenue? | $1.90M | $5.30M | $4.82M | $4.76M | $5.25M | $3.59M | $2.13M | $2.36M |
| Gross Profit? | $24,110 | $3.99M | $5.11M | $5.65M | $5.89M | $4.60M | $2.17M | $2.03M |
| Gross Margin? | +1.2% | +42.9% | +51.4% | +54.3% | +52.9% | +56.2% | +50.5% | +46.2% |
| Operating Expenses? | $9.00M | $16.72M | $16.28M | $15.83M | $11.81M | $7.01M | $6.05M | $5.39M |
| Operating Income? | -$8.98M | -$12.73M | -$11.17M | -$10.19M | -$5.93M | -$2.41M | -$3.88M | -$3.36M |
| EBITDA? | -$8.75M | -$12.73M | -$8.80M | -$8.80M | -$5.86M | -$1.74M | -$2.52M | -$3.79M |
| Income Before Tax | -$10.49M | -$12.50M | -$11.10M | -$10.25M | -$8.96M | -$4.65M | -$4.88M | -$5.47M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | -$157,000 | -$127,000 |
| Net Income? | -$10.49M | -$12.50M | -$11.10M | -$10.25M | -$8.96M | -$4.65M | -$4.73M | -$5.35M |
| EPS? | $-91.20 | $-703.20 | $-49.20 | $-818.80 | $-980.40 | $-5775.20 | $-4039.60 | $-4564.40 |
| Diluted EPS? | $-91.20 | $-703.20 | $-982.00 | $-817.60 | $-980.40 | $-5775.20 | $-4039.60 | $-4564.40 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality